Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Condition(s):Primary Immune Deficiency DisorderLast Updated:October 5, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Primary Immune Deficiency DisorderLast Updated:October 5, 2016Completed
Condition(s):Primary Immunodeficiency Diseases (PID)Last Updated:October 11, 2023Not yet recruiting
Condition(s):Primary Immune Deficiency DisorderLast Updated:April 5, 2012Completed
Condition(s):Primary ImmunodeficiencyLast Updated:July 7, 2015Unknown status
Condition(s):Primary Ciliary Dyskinesia; Kartagener Syndrome; Primary Immune DeficiencyLast Updated:April 13, 2023Recruiting
Condition(s):Primary Immune DeficienciesLast Updated:August 25, 2017Completed
Condition(s):Primary ImmunodeficiencyLast Updated:April 10, 2020Withdrawn
Condition(s):Severe Combined Immunodeficiency Disease; Severe Primary Immunodeficiency Disorder; Undefined T Cell Deficiency Disorder; Wiskott-Aldrick SyndromeLast Updated:July 2, 2013Terminated
Condition(s):Primary Immunodeficiency Diseases (PID)Last Updated:February 20, 2024Active, not recruiting
Condition(s):Primary ImmunodeficiencyLast Updated:June 16, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.